Geschäftsbericht der Lindenhofgruppe 2019

Thema Fachgebiet Ansprechperson Lindenhofgruppe Kooperations- partner /  Sponsor A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2-Directed Regimens in the Metastatic Setting (PUMA-NER 1301) Onkologie, Hämatologie Prof. Dr. med. Markus Borner Puma Biotechnology An international multi-centre study of tamoxifen vs anastro- zole in postmenopausal patients with carcinoma in situ (IBIS II DCIS) Onkologie, Hämatologie Prof. Dr. med. Markus Borner Queen Mary University of London An international multi-centre study of anastrozole vs placebo in postmenopausal patients at increased risk of breast cancer (IBIS II Prevention) Onkologie, Hämatologie Prof. Dr. med. Markus Borner Queen Mary Uni- versity of London, Schweizerische Arbeitsgemein- schaft für Klini- sche Krebsfor- schung A stratified, multicenter Phase II trial of transdermal CR1447 (4-OH-testosterone) in endocrine responsive-HER2 negative and triple negative-androgen receptor positive metastatic or locally advanced breast cancer (SAKK 21/12) Onkologie, Hämatologie Prof. Dr. med. Markus Borner Schweizerische Arbeitsgemein- schaft für Klini- sche Krebsfor- schung A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician’s Choice for Metastatic Triple Negative Breast Cancer (MK3475-119-0203) Onkologie, Hämatologie Prof. Dr. med. Markus Borner MSD MERCK SHARP & DOHME AG Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer (RESCUE) Onkologie, Hämatologie Prof. Dr. med. Markus Borner Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOG- GO), Campus Stiftung Linden- hof Bern (SLB) Analysis of clinical outcomes of therapy with Ranibizumab and Aflibercept compared to steroids in diabetic macular edema (ID: 2017-00143) Ophthalmologie Prof. Dr. med. Justus Garweg – Retrospective analysis of clinical outcomes after switching from Ranibizumab to Aflibercept (KEK-Nr. 099 / 15) Ophthalmologie Prof. Dr. med. Justus Garweg – Ocriplasmin Therapy for Symptomatic Vitreomacular Pathologies (ID: 2016-02084) Ophthalmologie Prof. Dr. med. Justus Garweg Stadtspital Triemli 77